

Transforming Growth Factor- β Levels in Human Aqueous Humor of Glaucomatous, Diabetic and Uveitic Eyes

Seong Hee Min, MD¹, Tong-Il Lee, MS¹, Yun Seok Chung, MD², Hwang Ki Kim, MD¹

Department of Ophthalmology, Kim's Eye Hospital, Myung-Gok Eye Research Institute,
Konyang University College of Medicine¹, Seoul, Korea

Department of Ophthalmology, Hallym University Sacred Heart Hospital,
Hallym University Medical Center, Hallym University College of Medicine², Pyeongchon, Korea

Purpose: Transforming growth factor- β_2 is known to be present at elevated levels in the aqueous humor of patients with primary open angle glaucoma (POAG) and diabetes but not in uveitis-related secondary glaucoma. We investigated total TGF- β_2 levels and levels of the active form of TGF- β_2 in the aqueous humor of eyes with different types of glaucoma.

Methods: The concentration of the total and active form of TGF- β_2 was measured in 63 patients with primary open angle glaucoma, neovascular glaucoma complicated with diabetes (NVG), and secondary open angle glaucoma complicated with uveitis (SOAG) using a double antibody 'sandwich-indirect' ELISA method.

Results: The levels of total TGF- β_2 in the aqueous samples of POAG, NVG, and SOAG were elevated. The levels of active TGF- β_2 in the aqueous samples of POAG, and NVG were also elevated, whereas the level of active TGF- β_2 was within the normal range in the aqueous samples of SOAG.

Conclusions: These results suggest that the level of TGF- β_2 may play a role in the pathology of various types of glaucoma. *Korean Journal of Ophthalmology* 20(3):162-165, 2006

Key Words: Aqueous humor, Neovascular glaucoma, Primary open angle glaucoma, Secondary open angle glaucoma, Transforming growth factor- β

Transforming growth factor- β s (TGF- β s) constitute a family of multifunctional polypeptides of approximately 25 kDa, and exhibit pleiotropic regulatory actions upon most vertebral cell types.^{1,2} Depending on the cell type, they regulate proliferation, migration, differentiation, cytokine production, synthesis of extracellular matrix (ECM), wound healing, immunosuppression, and *in vivo* angiogenesis.³ TGF- β exists in at least five genetically distinct isoforms, β_1 - β_5 .⁴ Among these, only three isoforms, namely β_1 , β_2 , and β_3 , are expressed in human ocular tissues.⁴

TGF- β_2 is regarded as the major isoforms in the eye.^{2,4} Elevated levels of TGF- β_2 have been detected in the aqueous humor of glaucomatous eyes,^{4,7} and reduced levels of active TGF- β_2 have been detected in the aqueous humor of uveitic eyes.⁸

Received: May 13, 2005 Accepted: July 7, 2006

Reprint requests to Hwang Ki Kim, MD. Department of Ophthalmology, Kim's Eye Hospital, Myung-Gok Eye Research Institute, Konyang University College of Medicine, #156 4-Ga, Yeongdeungpo-dong, Yeongdeungpo-ku, Seoul 150-034, Korea. Tel: 82-2-2639-7822, Fax: 82-2-677-9214, E-mail: eye1001@paran.com

* This study was presented in part at the 92th Annual Meeting of the Korean Ophthalmological Society, October, 2004.

* This study was supported by a grant from the Myung-Gok Eye Research Fund.

In this study, we evaluated levels of total TGF- β_2 and the active form of TGF- β_2 in the aqueous humor of patients with different types of glaucoma (POAG, NVG, and SOAG), using a sensitive and specific enzyme-linked immunosorbent assay (ELISA).

Materials and Methods

1. Materials

Aqueous humor was collected in the operating room from 63 eyes of 63 human subjects (age range, 19 to 83 years; mean \pm standard deviation, 49.88 \pm 17.58) undergoing cataract or glaucoma surgery.

Patients were classified into four groups: those with POAG (group P; 14 patients), those with NVG complicated with diabetes (group N; 14 patients), those with SOAG complicated with uveitis (group S; 15 patients), and those with only cataract (group C, control group; 20 patients).

In group P, the average preoperative intraocular pressure (IOP) was 21.8 \pm 5.7 mmHg. The patients had established diagnosis of advanced POAG that correlated with advanced visual field loss. The POAG patients received 2.51 \pm 0.76 anti-glaucoma medications, and none of the patients had previous ocular surgery of any kind. In group N, the average

preoperative IOP was 33.7 ± 6.2 mmHg. All patients had proliferative diabetic retinopathy with rubeosis iridis. The patients were treated with 2.23 ± 1.18 anti-glaucoma medications and panretinal photocoagulation (PRP). The anterior segment neovascularization was reduced in nine patients, but peripheral anterior synecia formation progressed. Five patients had peripheral anterior synecial closure at the time of PRP. In group S, the average preoperative IOP was 27.3 ± 4.7 mmHg. The patients had uveitis with anterior, intermediate, posterior, and panuveitis of different origins. In group C, patients underwent elective cataract extraction with intraocular lens implantation. All patients had a normal ocular examination. Patients were excluded if they were taking topical medication or had an ocular condition that was being treated with topical or systemic medications.

2. Interventions Preceding Aqueous Humor Sampling

All surgery was performed under local anesthesia, consisting of 2% lidocaine hydrochloride, administered by retrobulbar and nadir injection.

3. Collection of Aqueous Humor

All samplings were performed by the same surgeon. At the time of cataract or glaucoma surgery, a limbal paracentesis was made with a 20 G MVR knife (BD Ophthalmic systems, Bidford on Avon, Warks, B50 4JH, UK). Aqueous humor ($100\text{--}200 \mu\text{L}$) was aspirated into a tuberculin microsyringe prior to any incisional surgical procedures. All samples were rapidly frozen and stored in a -70°C freezer until analysis.

4. Detection and quantification of TGF- β_2 by ELISA

The concentration of TGF- β_2 in aqueous humor samples was quantified by a double antibody ‘sandwich-indirect’ enzyme-linked immunosorbent assay (R&D Systems, Minneapolis, MN, U.S.A.), with a sensitivity of 2 pg/ml. Intra- and inter-assay coefficients of variation for ELISA were within 7%. The concentration of TGF- β_2 in the aqueous humor samples was determined by comparison with a standard curve of activity of standard TGF- β_2 .

Briefly, $100 \mu\text{L}$ standard TGF- β_2 or aqueous humor sample was added to a 96-well ELISA plates coated with murine monoclonal anti-TGF- β_2 -antibodies. After 2 hours of incubation at room temperature, the wells were washed three times with $400 \mu\text{L}$ wash buffer. Each well was coated with $200 \mu\text{L}$ of polyclonal anti-TGF- β_2 antibodies conjugated to horseradish peroxidase. The mixture was incubated and washed, as previously described. $200 \mu\text{L}$ substrate solution was added to each well, and the plate was incubated for 20 minutes at room temperature to allow the reaction to proceed. $50 \mu\text{L}$ stop solution was then added to each well. Absorbance at 450 nm was measured with an immunoreader system (BIO-TEK, Winooski, VT, USA).

5. Acid Activation of the Aqueous Humor Samples

For the determination of total TGF- β_2 , all of the aqueous humor samples were treated with $10 \mu\text{L}$ 1N HCl, and left for 10 minutes at room temperature to allow activation. Then, $10 \mu\text{L}$ 1.2 N NaOH/0.5 M HEPES was added for neutralization, and diluted with $340 \mu\text{L}$ Calibrator Diluent. Determination of total TGF- β_2 was performed immediately.

6. Statistical Analysis

Statistical analysis was performed, using the Kruskall-Wallis




Fig. 1. Concentration of total transforming growth factor (TGF)- β in the aqueous humor of different types of glaucoma.




Fig. 2. Concentration of active transforming growth factor (TGF)- β_2 in the aqueous humor of different types of glaucoma.

test program. A multiple comparison was conducted, using the Mann-Whitney test. Significant differences were defined by P values below 0.05.

Results

The concentration of total and active TGF- β_2 in each group are shown in Fig. 1 and 2. The concentrations of total TGF- β_2 (mean±standard deviation) in the aqueous humor are shown in Fig. 1. The mean concentration of total TGF- β_2 in groups P, N, and S was 3824±890 pg/ml, 3264±221 pg/ml, and 1984±539 pg/ml, respectively. These values were significantly higher than that of group C (1392±177 pg/ml, p<0.05).

The concentrations of active TGF- β_2 (mean±standard deviation) in the aqueous humor are shown in Fig. 2. The concentration of active TGF- β_2 in the aqueous humor of groups P, N, and S was 397±147 pg/ml, 535±126 pg/ml, and 277±136 pg/ml, respectively, compared with 233±66 pg/ml for group C. Active TGF- β_2 levels in groups P and N were statistically significantly higher than that of the control group C (p<0.05).

Discussion

The physiologic function of TGF- β_2 in the tissue of the eye is not yet fully understood. TGF- β_2 has previously been shown to increase accumulation of ECM components and stimulate neovascularization.^{7,9-10} TGF- β_2 is thought to play an important role in the immunosuppressive function of aqueous humor for the maintenance of anterior chamber-associated immune deviation (ACAID).¹¹

Tripathi et al.¹⁰ reported that the mean concentrations of total and active TGF- β_2 in the aqueous humor of POAG were 2700 pg/ml and 450 pg/ml, respectively, compared with 1480 pg/ml and 200 pg/ml in the control group. Our study confirmed that the levels of both total and active TGF- β_2 were significantly higher in group P than in group C. TGF- β_2 plays a regulatory role in the accumulation of ECM by stimulating the synthesis and secretion of matrix proteins and protease inhibitors, and inhibits the synthesis of proteolytic enzymes.¹² It also inhibits proliferation and migration of trabecular cells *in vitro*.¹³ Thus, high levels of total and active TGF- β_2 may contribute to the development of outflow resistance in the pathogenesis of POAG.

Ochiai et al.⁹ reported total TGF- β_2 levels of 1716 pg/ml, and 1001 pg/ml, respectively, in the aqueous of diabetics and control eyes. Another study reported that the concentrations of total and active TGF- β_2 in the vitreous of patients with proliferative diabetic retinopathy (PDR) were 2634 pg/ml and 244 pg/ml, respectively.¹⁴ The levels of total and active TGF- β_2 in the vitreous of nondiabetic subjects were 1305 pg/ml and 79 pg/ml, respectively.¹⁴ We showed elevated levels of both total and active TGF- β_2 in NVG related to diabetes. An elevated concentration of TGF- β_2 in the aqueous humor of

patients with NVG complicated with diabetes may result in neovascularization. Therefore, the production of TGF- β_2 in the eyes of NVG patients may have a different outcome from that in the eyes of POAG patients.

TGF- β_2 in aqueous humor contributes to the fluid's immunosuppressive function and inhibits T-cell proliferation. Decreased levels of TGF- β_2 in the aqueous humor of uveitis have been reported in a previous study.⁸ It has been reported that macroglobulin present in the serum binds TGF- β , inhibiting activation. The presence of such proteins in the aqueous humor of uveitic patients may lower the level of active TGF- β_2 .⁸ In this study, the level of active TGF- β_2 was not elevated when compared with the control; in fact, since the total level of TGF- β_2 in SOAG was higher than that of the control, the relative concentration of active TGF- β_2 is lower in the SOAG patients. Further studies will be required to improve our understanding of the roles of TGF- β_2 in the aqueous humor of various types of glaucomatous eyes.

This study is the first report of increased levels of TGF- β_2 in the aqueous humor of NVG complicated with diabetes in Korea. We demonstrate elevated concentrations of total TGF- β_2 in the aqueous humor of patients with POAG, NVG, and SOAG. The concentrations of active TGF- β_2 in the aqueous humor are also elevated in POAG, and NVG, while the relative concentration of active TGF- β_2 in SOAG is decreased. TGF- β_2 may play a role in the pathology of various types of glaucoma. Further studies will be needed to elucidate the therapeutic implications for TGF- β_2 as an anti-inflammatory or immunosuppressant agent in the treatment of glaucoma.

References

1. Imanishi J, Kamiyama K, Iguchi I, et al. Growth factors: importance in wound healing and maintenance of transparency of the cornea. *Prog Retin Eye Res* 2000;19:113-29.
2. Kokawa N, Sotozono C, Nishida K, Kinoshita S. High total TGF- β levels in normal human tears. *Curr Eye Res* 1996; 15:341-3.
3. Roberts AB, Sporn MB. The transforming growth factor- β s. In: Sporn MB, Roberts AB, eds. *Handbook of Experimental Pharmacology*. Heidelberg: Springer-Verlag, 1990;95:419-72.
4. Nishida K, Sotozono C, Adachi W, et al. Transforming growth factor-beta 1, -beta 2, and -beta 3 mRNA expression in human cornea. *Curr Eye Res* 1995;14:235-41.
5. Jampel HD, Roche N, Stark WJ, Roberts AB. Transforming growth factor- β in human aqueous humor. *Eye Res* 1990;9: 963-9.
6. Tanihara H, Inatani M, Honda Y. Growth factor and their receptors in the retina and pigment epithelium. *Prog Ret Eye Res* 1997;16:271-301.
7. Inatani M, Tanihara H, Katsuta H, et al. Transforming growth factor- β_2 in aqueous humor of glaucomatous eyes. *Graefe's Arch Clin Exp Ophthalmol* 2001;239:109-13.
8. Boer JH, Limpens J, Orengo-Namia S, et al. Low mature TGF- β_2 in aqueous humor during uveitis. *Invest Ophthalmol Vis Sci* 1994;35:3702-10.
9. Ochiai Y, Ochiai H. Higher concentration of transforming growth factor- β in aqueous humor of glaucomatous eyes and diabetic eyes. *Jpn J Ophthalmol* 2002;46:249-53.

10. Tripathi RC, Li J, Chan WF, Tripathi BJ. Aqueous humor in glaumatous eyes contains an increased level of TGF- β_2 . *Exp Eye Res* 1994;9:723-8.
11. Cousins SW, McCabe MM, Danielpour D, Streilein JW. Identification of transforming growth factor- betas as an immunosuppressive factor in aqueous humor. *Invest Ophthalmol Vis Sci* 1991;32:2201-11.
12. Yamashita H. Functions of the transforming growth factor- β superfamily in eyes. *J Jpn Ophthalmol Soc* 1997;101:927-47.
13. Borisuth NSC, Tripathi BJ, Tripathi RC. Identification and partial characterization of TGF- β_1 receptors on trabecular cells. *Invest Ophthalmol Vis Sci* 1992;3:407-14.
14. Hirase K, Sotozono C, Ikeda T, et al. Transforming growth factor beta2 in the vitreous in proliferative diabetic retinopathy. *Arch Ophthalmol Vis Sci* 1998;116:738-41.